The ABHD12 Knockout Jurkat Polyclonal Cells product offers a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat human T lymphocyte line, engineered for targeted disruption of the ABHD12 gene. This polyclonal pool comprises a heterogeneous collection of loss-of-function alleles generated by CRISPR-mediated gene editing, eliminating the need for single-cell cloning. The model enables robust investigation of ABHD12??s enzymatic role in degrading lysophosphatidylserine (lyso-PS), a key lipid mediator in immune signaling. Researchers can leverage this system to dissect ABHD12-dependent pathways within a well-characterized T-cell background, without the biases of clonal selection.
The Jurkat parental line, originally isolated from the peripheral blood of an acute T-cell leukemia patient, is an immortalized human T lymphocyte model extensively employed in immunology and oncology research. Jurkat cells are instrumental for studying T-cell receptor signaling, activation cascades, cytokine production, and leukemogenic processes. Their stable suspension growth, robust proliferative capacity, and thoroughly annotated molecular landscape make them an ideal host for gene-editing applications, particularly for examining signal transduction mechanisms that govern immune responsiveness.
ABHD12 encodes a serine hydrolase that critically controls lyso-PS turnover; this lipid functions as a high-affinity agonist for the G protein-coupled receptor GPR34, modulating immune cell function and neuroinflammation. In unmodified Jurkat cells, ABHD12 hydrolyzes lyso-PS, preventing excessive ligand accumulation. CRISPR/Cas9-mediated ABHD12 disruption impairs this degradation, resulting in elevated extracellular lyso-PS and sustained GPR34 stimulation, which in turn dysregulates downstream MAPK/ERK and NF-kB signaling cascades. Pro-inflammatory stimuli such as TNF-alpha and Toll-like receptor ligands (e.g., LPS) act upstream to modulate ABHD12 expression, integrating lipid metabolic control with canonical immune pathways. Consequently, the ABHD12-lyso-PS-GPR34 axis operates through ERK1/2 and NF-kB to fine-tune T-cell activation states.
Within Jurkat T lymphocytes, ABHD12 knockout provides a physiologically relevant platform to model the lipid metabolic imbalances characteristic of PHARC syndrome, a rare neurological disorder linked to loss-of-function ABHD12 mutations. The polyclonal nature of the knockout population recapitulates a heterogeneous genetic ablation landscape, mirroring the variety of mutations encountered in disease states. This system enables detailed examination of how lyso-PS accumulation alters adaptive immune functions??including antigen-driven activation, cytokine release, and differentiation??and facilitates exploration of the crosstalk between lipid signaling and T-cell biology, with implications for both neuroimmunology and leukemic progression.
Typical applications encompass quantitative analysis of lyso-PS by LC-MS, assessment of immune activation markers (e.g., CD69, CD25) via flow cytometry, and evaluation of MAPK/ERK pathway activity through phospho-ERK Western blotting. Cytokine secretion assays for IL-2 and IFN-gamma measure functional T-cell responses following ABHD12 loss. RT-qPCR and immunoblotting for ABHD12 are essential for confirming gene disruption and downstream effects. The model also supports drug screening initiatives targeting lipid metabolic disorders or neuroinflammatory components of PHARC syndrome. For detailed protocols, technical specifications, or ordering, please contact Ascent Research.
